Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome identifier:
NCT05078866 (

Prevention study for people with Lynch syndrome

Study Contact Information:

For additional information, please contact:  

MD Anderson Cancer Center’s office of: Eduardo Vilar-Sanchez at 713-563-4743 or [email protected]

About the Study

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.

People with Lynch syndrome who enroll in the study will participate for one year. It evaluates the safety and effectiveness of the Nous-209 vaccine in people affected with Lynch syndrome.

What the Study Involves

People enrolled in this study will receive a vaccine on day 1 and week 8 of this study. The two vaccines work together to build an immune response (immunity) against colon cancer among people with Lynch syndrome. After the completion of the vaccines, the study will follow up with participants at 16, 24, 36, and 52 weeks.

People enrolled in the study will be asked to complete health questionnaires and have blood tests to determine how their body is responding to the vaccine. Additional procedures such as colonoscopies and endoscopies may be necessary to check the colon for polyps.

Study Sites


City of Hope Comptehensive Cancer Center
Contact: Gregory E. Idos 626-256-4673 [email protected]


Fox Chase Cancer Center   
Contact: Michael J. Hall 215-728-2861 [email protected]


MD Anderson Cancer Center 
Contact: Eduardo Vilar-Sanchez 713-563-4743 [email protected]

Puerto Rico

San Juan
University of Puerto Rico 
Contact: Marcia R. Cruz-Correa 787-758-2525 [email protected]


This Study is Open To:

People 18 years of age or older may be eligible if they have or agree to the following:

This Study is Not Open To:

People cannot enroll if they:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.